IMMU-107-04: An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Cancer - Pancreatic
Principal Investigator: Gazala N Khan, MD
This is a double-blind, randomized phase 3 study of 90Y-clivatuzumab tetraxetan with low-dose gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer patients who have progressed on at least 2 prior therapies for metastatic cancer (1 of which was a gemcitabine-containing regimen).
- Histologically or cytologically confirmed adenocarcinoma of the pancreas
- Metastatic disease
- Received at least two prior systemic cytotoxic chemotherapy regimens for unresectable, locally advanced or metastatic disease
Please contact us for a full list of eligibility criteria.